On Monday, Northern Trust Corporation (NASDAQ:NTRS)’s shares declined -0.01% to $70.02.
Northern Trust Corporation declared that Chairman and Chief Executive Officer Frederick H. Waddell will speak at the Barclays Global Financial Services Conference on Wednesday, September 16, 2015 at 9:45 a.m. (ET) at the New York Hilton Midtown.
Northern Trust Corporation, a financial holding company, provides asset servicing, fund administration, asset administration, fiduciary, and banking solutions for corporations, institutions, families, and individuals worldwide. It operates in two segments, Corporate & Institutional Services (C&IS) and Wealth Administration.
Ingredion Inc (NYSE:INGR)’s shares gained 0.72% to $83.87.
Ingredion Incorporated (INGR), a leading global provider of ingredient solutions to diversified industries, declared recently that it plans to consolidate its manufacturing network in Brazil. Plants in Trombudo Central and Conchal will be closed and production will be moved to plants in Balsa Nova and Mogi Guaçu, respectively.
The consolidation will start early in 2016 and should be complete by the end of the year. It is predictable to result in annual cost savings of $6 - 8 million USD startning in 2017. Total pre-tax restructuring-related charges of $13 - 16 million USD are anticipated in the third quarter of 2015.
“We continuously evaluate our manufacturing network for improvement opportunities. Consolidating production into Balsa Nova and Mogi Guaçu is part of our overall restructuring program in our Brazilian operations to reduce costs in our network,” said Ricardo Souza, president, Ingredion South America.
Ingredion Incorporated, together with its auxiliaries, manufactures and sells starches and sweeteners to various industries. It offers sweetener products comprising glucose syrups, high maltose syrups, high fructose corn syrups, caramel colors, dextrose, polyols, maltodextrins and glucose, and syrup solids, in addition to food-grade and industrial starches.
At the end of Monday’s trade, LivePerson, Inc. (NASDAQ:LPSN)‘s shares dipped -9.84% to $8.25.
LivePerson, Inc. (LPSN), a leading provider of digital engagement solutions, recently declares that the Company will be presenting at two forthcoming investor conferences in September. LivePerson CEO Rob LoCascio and CFO Dan Murphy will be attending the following investor conferences:
Credit Suisse 6th Annual Small & Mid Cap Conference
Wednesday, September 16th at 10:50 a.m. ET
The Waldorf Astoria in New York, New York
Attendee: Rob LoCascio, CEO
Deutsche Bank 2015 Technology Conference
Thursday, September 17th at 8:50 a.m. PT
The Cosmopolitan in Las Vegas, Nevada
Attendee: Dan Murphy, CFO
LivePerson, Inc. provides online engagement solutions that facilitate real-time assistance and expert advice in the United States, Canada, Latin America, South America, Europe, the Middle East, Africa, and the Asia-Pacific. It operates in two segments, Business and Consumer. The company facilitates real-time online interactions, such as chat, voice, and content delivery across various channels and screens for corporations of various sizes; and facilitates online transactions between independent service providers and individual consumers seeking information and knowledge for a fee via real-time chat.
Foundation Medicine Inc (NASDAQ:FMI), ended its Monday’s trading session with 8.18% gain, and closed at $25.67.
Foundation Medicine, Inc. (FMI) declared that members of the company’s administration team will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2015, at 9:55 a.m. EDT in New York City.
Foundation Medicine, Inc. provides various molecular information products in the United States. Its molecular information platform comprises proprietary methods and algorithms to analyze specimens across various types of cancer, in addition to for incorporating that information into clinical care; and offers genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
